| GENMAB AS DK 1 | 300.70 / -0.17% |
| Date/Time | 05/13 / 18:46 |
| Chg. / Chg.(%) | -0.50 / -0.17% |
| Bid | - |
| Ask | - |
| Open | 300.30 |
| Previous Close | 301.20 |
| High | 301.00 |
| Low | 292.60 |
| Volume [EUR] | 0.00 |
| Volume [Units] | 0 |
| Price fixings | 12 |
| ISIN | DK0010272202 |
| Security | GE9 |
| Exchange | Berlin |
| Type | Stock |
Other Exchanges
| Exchange | Last | Volume | |
|---|---|---|---|
| TradeGate | 297.300 |  |
193 |
| Nasdaq Other.. | 372.7200 |  |
174 |
| Vienna Globa.. | 300.60 | |
0 |
| München | 305.60 | |
0 |
| Düsseldorf | 299.00 | |
0 |
| Frankfurt | 297.2000 |  |
0 |
| Berlin | 300.70 | |
0 |
| Stuttgart | 299.100 | |
0 |
| London Inter.. | 2,229.0 | |
|
| Lang & Schwa.. | 299.60 | |
|
| gettex | 299.700 | |
|
| OMX Nordic | 2,231.00 | 139,142 | |
| Cboe Europe .. | 2,230.00 | 26,191 | |
| Turquoise | 2,231.00 | |
8,762 |
| Cboe Europe .. | 2,252.00 | 4 | |
| Cboe Europe .. | 2,226.00 | 725 | |
| Mexico | 7,638.15 | |
11,330 |
News
- Genmab Announces Financial Results for the First Quarter of 2021
05/05/2021 / 17:01 - GlobeNewswire - Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2021
04/20/2021 / 12:34 - GlobeNewswire - Genmab and Seagen Announce U.S. FDA Filing Acceptance for Priority Review of Tisotumab Vedotin Biologics License Application for Patients with Recurrent or Metastatic Cervical Cancer
04/09/2021 / 22:00 - GlobeNewswire - Genmab Announces European Marketing Authorization for Kesimpta® (ofatumumab) in Relapsing Multiple Sclerosis
03/30/2021 / 07:21 - GlobeNewswire - Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
02/25/2021 / 20:53 - GlobeNewswire
Real-time